Article Sidebar

Submitted
May 21, 2021
Published
May 21, 2021
Download
PDF
Statistic
Read Counter : 33 Download : 27

Main Article Content

Abstract

Aim: The aim of this study was to analyze the neurological adverse drug reactions of anticancer drugs that were reported to adverse drug reaction monitoring centre.


Methods:The entire neurological adverse drug reactions (ADRs) reported with anticancer drugs, received through spontaneous reporting system and active surveillance method from January 2012 to September 2013 were analyzed for demographic profile, ADR pattern, severity and causality assessment.


Results: During the study period, a total of 1418 anticancer drug related ADRs were obtained from 1076 patients; among them 84 (5.9%) reactions were neurological. Totally 77 patients developed 84 neurological ADRs. Among them 42 were males (54.5%) and 35 were females (45.5%). CAPOX (Capecitabine and oxaliplatin) was the leading drug regimen among agents causing neurological ADRs accounting for 15.5%. The most frequently reported ADR was neuropathy (72.6%). According to WHO causality assessment of ADRs, majority of the reports come under possible (89.6%) category. Hartwig severity scale showed that 57.1% of the reactions were moderately severe.


Conclusion: The frequency of neurological adverse drug reactions of anticancer drugs obtained was found to be 5.9%. Capecitabine and oxaliplatin regimen is the major causative agent among the anticancer drugs for neurological ADRs. Our study provided the analysis of neurological ADRs occurring due to anticancer agents.

Keywords

Adverse drug reactions anticancer drugs Neurological neurotoxicity

Article Details

How to Cite
M Palaniappan, SK Srinivasamurthy, B Dubashi, SA Dhkar, & A Chandrasekaran. (2021). Neurological adverse drug reactions of anticancer drugs. International Journal of Research in Pharmacology & Pharmacotherapeutics, 3(3), 152-157. https://doi.org/10.61096/ijrpp.v3.iss3.2014.152-157
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1] Nerurkar RP, Nadkar MY, Bichile SK. Need for monitoring adverse drug reactions. J Assoc Physicians India. 46, 1998, 673-4.
  2. [2] Jose J., Rao PG. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital. Pharmacol Res.54, 2006, 226-233.
  3. [3] Cancer Research in ICMR Achievements in Nineties, 1994.
  4. [4] Cavaliere R, Schiff D. Neurologic toxicities of cancer therapies. Curr Neurol Neurosci Rep. 6(3), 2006, 218-26.
  5. [5] Sarah EJ, Hubert B, Russell B, Youmei X, Tao Y, Stephen MM, Frank ML, Qun L. Anti-cancer drug induced neurotoxicity and identification of rho pathway signaling modulators as potential neuroprotectants. Neurotoxicology. 29(4), 2008. 605–612.
  6. [6] Newton HB. Neurological complications of chemotherapy to the central nervous system. Handb Clin Neurol. 105, 2012, 903-16.
  7. [7] Lindquist M. Vigibase, the WHO Global ICSR Database System: Basic Facts. Drug Inf J. 42, 2008, 409- 19.
  8. [8] Ich Harmonised Tripartite Guideline, Pharmacovigilance Planning E2E, Current Step 4 version, dated 18 November 2004.
  9. [9] Meyboom RH, Hekster YA, Egberts AC, Gribnau FW, Edwards IR. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf. 17(6), 1997, 374-89.
  10. [10] Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 49, 1992, 2229-32.
  11. [11] Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP. A review on oxaliplatin- induced peripheral nerve damage. Cancer Treat Rev. 34(4), 2008, 368-77.
  12. [12] Saif MW, Wood TE, McGee PJ, Diasio RB. Peripheral neuropathy associated with capecitabine. Anticancer Drugs. 15(8), 2004, 767-71.
  13. [13] Jim C, Josep T, Chris T, René B, Charles B, Thierry C, Filippo D, Arie F, Johannes G, Noriaki S, Patrick S, Alberto S, Eric VC, Eduardo D. XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer. J Clin Oncol. 22, 2004, 2084-2091.
  14. [14] Storey DJ, Sakala M, McLean CM, Phillips HA, Dawson LK, Wall LR, Fallon MT, Clive S. Capecitabine Combined with Oxaliplatin (CapOx) in Clinical Practice: How Significant is Peripheral Neuropathy?. Ann Oncol. 21(8), 2010, 1657-1661.
  15. [15] Verstappen CC, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, Kiburg B, Postma TJ. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology. 64(6), 2005, 1076-7.
  16. [16] Tschop K, Rommel F, Schmidkonz P, Emmerich B, Schulze J. Neuropathy after cyclophosphamide high dose chemotherapy in a Morbus Werlh of patient. Dtsch Med Wochenschr. 126 (12), 2001, T17-T20.
  17. [17] J B Cavanagh. Sensorimotor neuropathy and cisplatin and adriamycin toxicity. J Neurol Neurosurg Psychiatry. 49(8), 1986, 964–965.
  18. [18] Charity DS, William DF, Alex S. Peripheral Neuropathy Induced by Paclitaxel: Recent Insights and Future Perspectives. Curr Neuropharmaco., 4(2), 2006, 165–172.
  19. [19] Olivier Ha, Jean-Pierre L, Etienne R. Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy. J Neurol Neurosurg Psychiatry. 64, 1998, 667-669.
  20. [20] Argyriou AA, Polychronopoulos P, Iconomou G, Koutras A, Kalofonos HP, Chroni E. Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies. J Neurol. 252(12), 2005, 1459-64.
  21. [21] Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 112(5), 2008, 1593-9